每经记者:许立波每经编辑:张海妮丨 2024年11月20日 星期三 丨NO.1 君实生物:签署两款双靶点融合蛋白的许可协议11月19日,君实生物公告称,公司与许可方签署《许可协议》,获得在大中华区内开发、制造、使用、进口、出口、销售两款双靶点融合蛋白的独占许可权利。公司将在项目进展中向许可方支付150万美元首付款,并根据研发进展支付累计不超过7.4亿元的里程碑款。此外,许可方可能向公司支付大中华区...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.